Shobita Parthasarathy

Shobita Parthasarathy is a professor of public policy and women's and gender studies at the University of Michigan. She is also the co-founder and director of the Science, Technology and Public Policy Program there. Her work focuses on how technology can be used to address societal challenges, particularly in areas such as health care, energy production, and environmental protection. In her writing and research, she often explores issues related to gender equity and public policy. Parthasarathy has published numerous articles in academic journals and popular media outlets on topics including gene editing technologies like CRISPR, artificial intelligence's impact on society, the role of women in STEM fields, and the implications of big data for privacy and democracy.

Biography:  https://www.scientificamerican.com/author/shobita-parthasarathy/

86%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author has a mixed reputation for journalistic standards. It is advisable to fact-check, scrutinize for bias, and check for conflicts of interest before relying on the author's reporting.

Bias

80%

Examples:

  • People already struggle to get treatment for sickle cell disease, so reducing the cost of gene therapies will not make treatment any more accessible.
  • Reducing costs for these therapies is important. It is unlikely to make life much better for most people with sickle cell and those with other genetic diseases, however.
  • They might also encourage collaborations across the clinical, social and basic research arms of the National Institutes of Health rather than defining research projects according to scientific or medical specialty?
  • What if governments must change who sets research agendas and how?

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

100%

Examples:

  • Yet immediately after the approvals, attention turned to the prohibitive cost of the treatments.

Deceptions

75%

Examples:

  • Many people hope that these treatments will provide a 'functional cure' for the genetic condition, which causes rigid, misshapen red blood cells that lead to anemia, episodes of extreme pain, blood vessel and organ damage, stroke risk and lower life expectancy.
  • Reducing costs for these therapies is important. It is unlikely to make life much better for most people with sickle cell and those with other genetic diseases, however.

Recent Articles

New Gene Therapies and Innovative Approaches: Advancing Treatments for Sickle Cell Disease

New Gene Therapies and Innovative Approaches: Advancing Treatments for Sickle Cell Disease

Broke On: Tuesday, 21 May 2024 Two new gene therapies for sickle cell disease, approved in fall 2023, offer hope for a functional cure but raise questions about accessibility and equity. Researchers also explore alternative treatments like stem cell transplants from umbilical cord blood and small molecules that modulate gene expression. The goal is to develop accessible, effective, and equitable treatments for sickle cell disease.